Mike Stobbe from The Associated Press, October 2, 2015
NEW YORK (AP) — Five Americans came down with an unusual illness after traveling to Germany for a controversial treatment involving injections with sheep cells, health officials reported Wednesday.
The treatment is not permitted in the United States. The five New York residents received the "live cell therapy" in May last year. About a week later, they developed fever, fatigue and other symptoms of a dangerous bacterial illness called Q fever.
Two told investigators that they were part of a group that, for the last five years, had traveled to Germany twice a year for the injections. They said they get them to improve their health and vitality. There is no published clinical proof the treatments work, health officials say.
The Centers for Disease Control and Prevention on Wednesday released a report on the outbreak, which included a Canadian case — another medical tourist who got the treatment in Germany at about the same time. The four women and two men ranged in age from 59 to 83.
Three of the six recovered. But three others were still experiencing symptoms more than nine months later, health officials said.
Live or fresh cell therapy involves injecting people with fetal cells from sheep. It's sometimes offered as an anti-aging therapy, but also has been touted as a treatment for conditions ranging from impotence to migraines to liver disease.
Q fever is caused by a hardy germ found in cattle, sheep and goats. People usually get it from inhaling barnyard dust — it's an occupational hazard for farmers.
But cases in the U.S. are unusual — each year fewer than 200 are reported. It is treated with antibiotics and U.S. residents rarely die from Q fever; three or four deaths are reported in the worst years.
The cases were reported by health officials in the upstate New York counties of Erie and Ulster.
The report: http://www.cdc.gov/mmwr
This article was written by Mike Stobbe from The Associated Press and was legally licensed through the NewsCred publisher network.